Page 111 - Read Online

Page 14 of 16 Brunsing et al. Hepatoma Res 2020;6:59 I http://dx.doi.org/10.20517/2394-5079.2020.50

Copyright
© The Author(s) 2020.

REFERENCES
1. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol
2004;130:417-22.
2. Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: a systematic review.
World J Clin Cases 2019;716:2269-86.
3. Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, et al. Hepatocellular carcinoma surveillance with ultrasound - cost-
effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol
2018;69:182-236.
5. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-pacific clinical practice guidelines on the management of hepatocellular
carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
6. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018
Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
7. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan
Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatology Res 2019;4910:1109-13.
8. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC), Goyang, Korea. 2018 Korean Liver Cancer Association-
National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2019;13:227-99.
9. LI-RADS. American College of Radiology; Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-
RADS. [Last accessed on 13 Jul 2020]
10. Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018
update. Clin Mol Hepatol 2019;25:245-63.
11. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, et al. Accuracy of ultrasonography, Spiral CT, magnetic resonance, and alpha-
fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;10:513-23.
12. Kim SY, An J, Lim YS, Han S, Lee JY, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of
hepatocellular carcinoma. JAMA Oncol 2017;3:456-63.
13. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular
carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
14. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, et al. Surveillance Imaging and alpha fetoprotein for early detection of
hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.e1.
15. Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with
ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:161-7.
16. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, et al. Accuracy of ultrasonography, Spiral CT, magnetic resonance, and alpha-
fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-23.
17. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl
2018;24:1171-7.
18. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with
cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793-9.
19. Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, et al. Comparative 13-year meta-analysis of the sensitivity and positive
predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 2016 41:71-90.
20. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver
Dis 2010;30:61-74.
21. Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma
2016;3:41-53.
22. Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82.
23. Kim YK, Kim YK, Park HJ, Park MJ, Lee WJ, et al. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for
detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magn Reson Imaging 2014;32:610-8.
24. Han S, Choi JI, Park MY, Choi MH, Rha SE, et al. The diagnostic performance of liver MRI without intravenous contrast for detecting
hepatocellular carcinoma: a case-controlled feasibility study. Korean J Radiol 2018;19:568-77.
25. Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, et al. HCC screening: assessment of an abbreviated non-contrast MRI protocol.
Eur Radiol Exp 2019;3:49.
26. Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, et al. Evaluation of an abbreviated screening MRI protocol for patients at risk for
hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1627-33.
27. Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, et al. Abbreviated-protocol screening MRI vs. complete-protocol
diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. J Magn
Reson Imaging 2020;51:415-25.
28. Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic